Survodutide

Also known as: BI 456906

Weight LossPHASE 3

Clinical Status

Phase 3 clinical trials for obesity and MASH/NASH.

Mechanism of Action

Dual GLP-1 and glucagon receptor agonist. GLP-1 activation reduces appetite while glucagon activation increases energy expenditure and hepatic fat oxidation, providing complementary weight loss mechanisms.

Dosing Defaults

Dose

2.4-6 mg weekly

Frequency

Once weekly

Administration

Subcutaneous injection

Timing

Same day each week

Food

with or without

Duration

Long-term use expected

Dose range: 0.3-6 mg weekly (titrated)

Weekly injection with slow dose titration over weeks.

Side Effects

•Nausea
•Vomiting
•Diarrhea
•Decreased appetite
•Constipation
•Heart rate increase

Contraindications & Warnings

•Not medical advice
•Currently in Phase 3 trials

Compare

Compare Survodutide with another peptide side-by-side.

Calculate Dose

Use the reconstitution calculator to prepare your Survodutide dose.

Open Calculator

Related Weight Loss Peptides

Semaglutide

FDA APPROVED

Weight Loss

GLP-1 receptor agonist. FDA-approved for type 2 diabetes and weight management.

Tirzepatide

FDA APPROVED

Weight Loss

Dual GLP-1/GIP receptor agonist. FDA-approved for T2D and weight management.

Retatrutide

PHASE 3

Weight Loss

Triple receptor agonist (GLP-1/GIP/Glucagon). Most potent weight loss peptide in trials.

AOD-9604

PHASE 2

Weight Loss

GH fragment for fat metabolism. Does NOT produce typical HGH side effects.

This information is for educational purposes only and is not medical advice. Dosing data is based on research literature and community reports. Always consult a qualified healthcare provider before using any peptide.